1.
Clin Perinatol
; 51(1): 113-126, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38325937
RESUMO
Pulmonary hypertension in the neonatal population can be acute or chronic and carries significant risk for morbidity and mortality. It can be idiopathic but more often is associated with comorbid pulmonary and heart disease. There are several pharmacotherapeutics aimed at pulmonary vasodilation. This review highlights the most common agents as well as those on the horizon for the treatment of pulmonary hypertension in the neonate.